Health Boards
Proximagen Group plc (AIM: PRX), the rapidly growing company with a focus on the treatment of disorders of the central nervous system (CNS) and inflammatory diseases, announces that it had commenced dosing in a Phase I clinical trial of PRX167700, a Vascular Adhesion Protein-1 (VAP-1) antagonist, for the treatment of inflammation in rheumatoid arthritis (RA) and psoriasis.
Proximagen’s PRX167700 is an oral drug candidate that is expected to work by regulating the movement of immune cells from the blood into sites of inflammation, thereby modulating the underlying inflammatory process and relieving the symptoms of inflammation. This mode of action provides the potential for a disease modifying effect, whereby modulating the movement of the damaging immune cells to the sites of inflammation also stops further damage caused by the disease.
In addition to efficacy shown in models of RA, PRX167700 has demonstrated efficacy in models of multiple sclerosis and inflammatory pain. Regulating the movement of immune cells is also important in these two diseases, indicating that PRX167700 has potential utility in multiple disease areas of high unmet medical need.
This Phase I trial is a randomised, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of PRX167700 in healthy male subjects, and the effect of food on the pharmacokinetics of a single oral dose of the drug. The study will also investigate the relationship between the pharmacokinetic and pharmacodynamic effects of single and multiple ascending oral doses of PRX167700. The first results are anticipated in 2012.
Source: proximagen.com
Proximagen’s PRX167700 is an oral drug candidate that is expected to work by regulating the movement of immune cells from the blood into sites of inflammation, thereby modulating the underlying inflammatory process and relieving the symptoms of inflammation. This mode of action provides the potential for a disease modifying effect, whereby modulating the movement of the damaging immune cells to the sites of inflammation also stops further damage caused by the disease.
In addition to efficacy shown in models of RA, PRX167700 has demonstrated efficacy in models of multiple sclerosis and inflammatory pain. Regulating the movement of immune cells is also important in these two diseases, indicating that PRX167700 has potential utility in multiple disease areas of high unmet medical need.
This Phase I trial is a randomised, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of PRX167700 in healthy male subjects, and the effect of food on the pharmacokinetics of a single oral dose of the drug. The study will also investigate the relationship between the pharmacokinetic and pharmacodynamic effects of single and multiple ascending oral doses of PRX167700. The first results are anticipated in 2012.
Source: proximagen.com